Status:

COMPLETED

ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease

Lead Sponsor:

OPKO Health, Inc.

Conditions:

Alzheimer's Disease

Eligibility:

All Genders

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.

Eligibility Criteria

Inclusion

  • This study is open only to subjects who have completed the week 78 visit in Study ELND005-AD201 while taking their assigned dose of study drug medication.

Exclusion

  • Subject has no new medical contraindications to continued participation in the study.

Key Trial Info

Start Date :

June 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2011

Estimated Enrollment :

103 Patients enrolled

Trial Details

Trial ID

NCT00934050

Start Date

June 1 2009

End Date

June 1 2011

Last Update

October 21 2019

Active Locations (38)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (38 locations)

1

Banner Alzheimer's Institute

Phoenix, Arizona, United States, 85006

2

Sun Health Research Institute

Sun City, Arizona, United States, 85351

3

University of Arizona, Health Sciences Center, Dept. of Neurology

Tucson, Arizona, United States, 85724

4

Margolin Brain Institute

Fresno, California, United States, 93720

ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease | DecenTrialz